MA18.11 A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients

Extensive-stage small cell lung cancer (ES-SCLC) has limited treatment options with a median overall survival (mOS) of approximately 6 months when relapsed. We present results from Part 2 (dose expansion) of an ongoing Phase Ib/II study (NCT04434482) evaluating the combination of senaparib, a novel Poly (ADP-ribose) polymerase inhibitor, with temozolomide in relapsed ES-SCLC patients.